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ABSTRACT 
Aim There is uncertainty regarding the optimal sequence of surgery for patients with colorectal 
cancer (CRC) and synchronous liver metastases. This study was designed to describe temporal trends 
and inter-hospital variation in surgical strategy, and to compare long-term survival in a propensity 
score-matched analysis. 
 
Methods The National Bowel Cancer Audit dataset was used to identify patients diagnosed with 
primary CRC between 1st January 2010 and 31st December 2015 who underwent CRC resection in the 
English National Health Service. Hospital Episode Statistics data was used to identify those with 
synchronous liver-limited metastases who underwent liver resection. Survival outcomes of propensity 
score-matched groups were compared.  
 
Results Of 1830 patients, 270 (14.8%) patients underwent a liver-first approach, 259 (14.2%) a 
simultaneous approach and 1301 (71.1%) a bowel-first approach. The proportion of patients 
undergoing either a liver-first or simultaneous approach increased over the study period, from 26.8% 
in 2010 to 35.6% in 2015 (P<0.001). There was wide variation in surgical approach according to 
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hospital trust of diagnosis. There was no evidence of a difference in four-year survival between the 
propensity score-matched cohorts according to surgical strategy: bowel-first vs. simultaneous (HR 
0.92 (95% CI 0.80-1.06)) or bowel-first vs. liver-first ((HR 0.99 (95% CI 0.82-1.19)). 
 
Conclusion There is evidence of wide variation in surgical strategy in dealing with CRC and 
synchronous liver metastases. In selected patients, the simultaneous and liver-first strategies have 
comparable long-term survival to the bowel-first approach. 
 
WHAT DOES THIS PAPER ADD TO THE LITERATURE? 
This study has demonstrated that since 2010 there has been a growing popularity in English centres  
for the liver-first and the simultaneous approach in the management of colorectal cancer patients with 
synchronous liver-limited metastases. This has resulted in wide variation in surgical approach 
according to hospital trust of diagnosis.  
 
BACKGROUND 
20% of patients with colorectal cancer have liver metastases at the time of diagnosis [2, 3].  The 
treatment with the best chance of a cure is a complete resection of both the primary and related 
metastases.  
 
Conventional management of CRC patients with synchronous liver metastases, the ‘bowel-first’ 
approach, involves resection of the primary followed by liver resection [4]. Developments in 
radiology, surgical techniques and neoadjuvant treatment, coupled with improved understanding of 
liver functionǡhave led to alternative surgical sequences [5]. 
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The ‘simultaneous’ approach, resecting the liver metastases and CRC in the same procedure, carries 
the potential advantage of one anaesthetic and post-operative recovery period, reduced overall 
hospital stay and possible reduction of healthcare resources [6]. The ‘liver-first’ approach, where liver 
metastases are resected usually after a period of down-staging chemotherapy, and before resection of 
the primary, may optimize the chance of a curative resection by achieving earlier control of the liver 
disease [7].  
 
Patient fitness and the anatomical location and extent of liver metastases and primary CRC largely 
govern which strategy to employ. Simultaneous resection is typically performed when the CRC 
surgery does not involve pelvic dissection and the liver metastases are superficially located and 
amenable to resection without prolonged portal occlusion [5, 8-10]. The liver-first approach is used in 
patients with rectal cancer requiring neo-adjuvant chemoradiotherapy or with non-obstructive colonic 
cancer with liver metastases necessitating down-staging [11].  
 
The National Institute for Health and Care Excellence (NICE) recommends that if both the CRC and 
liver metastases are considered potentially resectable, the patient should be referred to a hepatobiliary 
multidisciplinary team (MDT) [12]. The hepatobiliary MDT, in conjunction with the colorectal MDT, 
will recommend a treatment pathway. Hepatobiliary surgical services in England have been 
centralized into a hub-and-spoke arrangement [13], and are present on-site in 27 of the 145 NHS 
hospital trusts that manage CRC patients in England [14].  
 
There are no randomised controlled trials comparing the three strategies and no study has previously 
described these at a national level. The aim of this study was to describe trends in surgical strategy 
over time and factors influencing patient selection. The study also sought to compare long-term 
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survival in patients undergoing either the liver-first or simultaneous approach compared to the bowel-
first strategy in a propensity score-matched analysis. 
 
METHODS 
Study population and data collection 
Data from the National Bowel Cancer Audit (NBOCA) [15] for patients diagnosed with primary CRC 
between 1st January 2010 and 31st December 2015 in English NHS hospital trusts, were linked to the 
Hospital Episode Statistics (HES) database [2]. The NBOCA collects data on all patients with newly 
diagnosed CRC in England. As the NBOCA involves analysis of data for service evaluation it is 
exempt from the UK National Research Ethics Committee approval.  
 
Patients recorded in the NBOCA dataset with synchronous liver-limited metastases undergoing an 
elective CRC resection and a liver resection formed the study cohort. Patients were excluded if they 
underwent emergency CRC surgery or had extra-hepatic disease at diagnosis.  
 
Data regarding hospital trust of diagnosis, surgical urgency, American Society of Anaesthesiologists 
(ASA) grade [3], pathological staging, and cancer site were obtained from NBOCA data. Date of 
death up to a cut-off date of 17th March 2017 was obtained from linked data from the Office for 
National Statistics (ONS) [16]. Patient socioeconomic status was derived from the Index of Multiple 
Deprivation (IMD) [17]. The IMD ranks 32482 geographical areas of England according to their level 
of deprivation measured across seven domains. Patients were grouped into five socioeconomic 
categories based on quintiles of the national ranking of these areas. The Royal College of Surgeons 
Charlson Score was used to identify International Classification of Diseases, Version 10 (ICD-10) 
codes of comorbid conditions in the HES records in the year preceding CRC diagnosis [18]. 
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The site of metastases was identified from HES data according to ICD-10 codes [19]. Synchronous 
metastatic disease was defined by a code for secondary malignant neoplasm of the liver (C787), or 
elsewhere (C780-784, C786, C790-96) recorded one year before, to three months after a diagnosis of 
CRC. A year prior to CRC diagnosis was chosen to include patients who are found to have metastases 
prior to determining the site of the CRC primary. Although NBOCA does not record the site of 
metastases, data completeness is 93% for M-stage at diagnosis in patients undergoing major resection. 
As HES data may under record liver metastases, patients with no HES code for liver metastases who 
were recorded as having M1 disease at diagnosis in NBOCA data undergoing a liver resection within 
a year of CRC diagnosis were included.  
 
Procedure information was captured in HES according to the Office of Population Censuses and 
Surveys classification, 4th revision (OPCS4) [20]. All HES records including admissions up to 1st 
January 2017 were searched for codes indicating a liver resection, portal vein embolization and 
radiofrequency ablation. Major liver resection was defined as right hemihepatectomy (J021), left 
hemihepatectomy (J022), extended right hemihepatectomy (J026) or extended left hemihepatectomy 
(J027). Minor liver resection was defined as resection of segment of liver (J023), wedge excision of 
liver (J024), partial excision of liver (J028/9), excision of lesion of liver (J031) and extirpation of 
lesion of liver (J038/9). Patients were deemed to have a two-stage liver resection when a further liver 
resection code was recorded within three months of the initial liver resection. 
 
Patients were considered to have a simultaneous resection when a liver resection code was recorded 
on the day of CRC resection, a liver-first approach if a liver resection code was recorded within the 
year preceding resection of CRC, or a bowel-first approach if a liver resection code was recorded 
within the year following CRC resection. 
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Statistical analysis and outcome measures 
As this study only includes patients in the staged groups who survive to undergo a second 
intervention, a traditional survival analysis from date of diagnosis would introduce bias in favour of 
bowel- and liver-first patients. This is because patients who die after the first procedure would be 
excluded by definition. Furthermore patients in the staged cohorts have their interventions at different 
time points following diagnosis. Therefore, a landmark analysis was undertaken to compare survival 
[21, 22]. This method, in which a period of time between a baseline date (date of diagnosis) and study 
start date (the landmark date) is designated the exposure period and selected a priori, is a standard 
approach for dealing with these issues. Only deaths after the landmark date were included in the 
analysis. Patients who die during the exposure window were excluded from analysis, leading to a 
characteristic plateau in the initial period of the survival curve, as seen in Figure 3. In this study, 
individuals who survived a minimum of 1 year after diagnosis (or if the second procedure had not 
been undertaken in the year following diagnosis more than 90-days from their second procedure) were 
included in the landmark analysis. Median follow-up from the date of diagnosis was 50 months. 
Therefore four-year survival was presented to avoid censoring the majority of patients. 
 
Characteristics of the treatment groups were compared using the Ȥ2 test. Due to differences in patient 
and disease characteristics in patients typically considered eligible for a liver-first or simultaneous 
approach, the choice of strategy for an individual patient is usually between the bowel-first approach 
and the liver-first approach, or the bowel-first approach and the simultaneous approach. Therefore two 
separate long-term survival comparisons were made: bowel-first vs. liver-first and bowel-first vs. 
simultaneous. The potential biases to the survival analysis associated with differences in patient 
characteristics were accounted for by propensity score matching. Propensity score matching can 
reduce biases associated with multivariable regression modelling because it restricts the comparison 
to only patients eligible for either approach [23]. Multivariable logistic regression models were used 
to generate the propensity scores. All variables in Table 1 were candidates for inclusion, with the 
exception of Charlson score where the individual indicator variable for each co-morbidity was 
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entered. One to one nearest neighbour matching without replacement was performed. The one to one 
ratio was chosen to minimise bias in accordance with recommendations [24]. Calipers of 0.33 were 
used (0.2 of the standard deviation of the logit of the propensity score) [25]. The distribution of all of 
the model factors in the bowel-first and the simultaneous group and the bowel-first and the liver-first 
group was compared. The balance in the co-variates across the treatment groups was considered to be 
achieved if the standardised differences were less than 10% [26].  
 
The Kaplan-Meier method was used to compare long-term survival in the matched and pre-matching 
cohort. Comparison of survival probabilities in the pre-matching group was performed with the log 
rank (Mantel–Cox) test. A Cox regression analysis was performed on the matched cohort using a 
robust standard error to allow for the clustering on the pairs.  
 
STATA® version 14.1 (StataCorp, College Station, Texas, USA) was used for analyses. 
 
RESULTS 
Patient selection and characteristics 
Of 1830 patients who underwent both a CRC and liver resection, 270 (14.8%) patients underwent a 
liver-first approach, 259 (14.2%) a simultaneous approach and 1301 (71.1%) a bowel-first approach. 
In 2015, the proportion of patients undergoing either a liver-first or simultaneous approach increased 
over the period, from 59 out of 249 patients (26.8%) in 2010 to 99 out of 278 patients (35.6%)  
(P<0.001) (Figure 1).  
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Baseline demographics and clinico-pathological characteristics for patients having both a liver 
resection and CRC resection according to treatment strategy are outlined in Table 1. Patients in the 
liver-first group were younger, had lower T-stage and N-stage and more commonly had a rectal 
cancer primary than patients in the bowel-first and simultaneous cohorts. In addition, a higher 
proportion had rectal cancer and underwent a major liver resection. Combined liver ablation, two-
stage resection and portal vein embolisation, were used more frequently in the liver-first cohort. 
 
In comparison, patients in the simultaneous group tended to be older, had a right-sided CRC primary 
tumour and typically underwent a minor liver resection. These patients were more commonly 
diagnosed in hospital trusts with on-site hepatobiliary services when compared to patients undergoing 
a bowel-first or liver-first approach.  
 
Variation by hospital trust of diagnosis 
There was wide variation in surgical strategy according to hospital trust of diagnosis (Figure 2). In 18 
out of 132 (13.6%) of hospital trusts, all patients diagnosed with synchronous liver-metastases who 
underwent a liver resection, were treated with the bowel-first approach. There were 19 hospital trusts 
(14.4%) in which more than 50% of patients underwent either the simultaneous or the liver-first 
approach.  
 
Survival 
Four-year survival in the landmark analysis for the unmatched cohort was 59% (95% confidence 
intervals (CI) CI 56-62) in the bowel-first group, 58% (95% CI 50-66) in the liver-first group and 
59% (95% CI 50-66) in the simultaneous group. Kaplan-Meier survival curves for the unmatched 
cohorts are shown in Figure 3A and B. 
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Matched survival analysis 
After propensity score-matching was performed across patients included in the landmark analysis, 
there were 198 matched bowel-first patients in the bowel-first vs. simultaneous comparison, and 207 
matched bowel-first patients in the bowel-first vs. liver-first comparison. The patient, tumour and 
operative characteristics of the bowel-first patients matched to the simultaneous cohort and those of 
the bowel-first patients matched to the liver-first cohort were quite different. Table 2 shows that the 
characteristics of the matched bowel-first patients reflect the patients in each of the simultaneous and 
liver-first cohorts. 
 
Kaplan-Meier survival curves for the matched cohorts are shown in Figure 3C and D. Survival 
analysis on the propensity score-matched groups showed there to be no evidence of a difference in 
four-year survival between the bowel-first and simultaneous cohort (hazard ratio (HR) 0.92 (95% CI 
0.80-1.06)), or between the bowel-first and liver-first cohort (HR 0.99 (95% CI 0.82-1.19)). Note that 
in Figure 3C and D the survival curve of the matched bowel-first patients is different due to the 
different patient characteristics of the two matched cohorts. 
 
DISCUSSION 
This population-based cohort study is the first to provide an overview of national practice in the 
management of patients presenting with CRC and synchronous liver-limited metastases. This study 
shows a growing popularity of the liver-first and simultaneous approach yet wide inter-hospital 
variation in patient management. The clinico-pathological characteristics of patients undergoing 
alternative strategies were quite distinct, confirming that these are generally performed in highly 
selected patients. There was no evidence of a long-term survival difference of the bowel-first strategy 
compared to the liver-first or simultaneous strategy.   
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The findings of this study are strengthened by having a large and recent patient cohort. The NBOCA 
database has a case ascertainment of 93% [15]. Furthermore, since financial reimbursement for NHS 
hospital trusts is co-ordinated through the recording of procedures in the HES database, the 
completeness of liver resection registration in HES is likely to be high.  Previous studies in this area 
have largely been from single institutions [27] and include patients diagnosed over a long time period 
[28]. Such studies have failed to include, or only have very small numbers in their liver first or 
simultaneous groups [9, 28-30], or they group the liver-first and bowel-first patients together as a 
“staged” cohort [31]. The largest previous population based study of the characteristics and outcomes 
of patients with synchronous CRC and liver metastases included patients diagnosed over a twenty 
year period (1982-2011) with only 28 patients in the liver-first group [28].  
 
The present study has some limitations primarily relating to possible missing data and lack of detail in 
the HES database. HES may under record liver metastases, and therefore patients were also included 
if they were recorded in NBOCA data as having M1 disease at disease and underwent a liver resection 
within a year of diagnosis even if they did not have a HES code of liver metastases. In addition, major 
liver resection is defined as the resection of three or more segments according to the code recorded in 
the HES database. This has the potential to misclassify patients undergoing non-anatomical resection 
of multiple single segments as minor liver resection. The HES database does not include information 
regarding the extent or distribution of liver metastases, an important factor in determining 
management decisions particularly regarding the use of simultaneous resection. It is however unlikely 
that the burden of liver metastases and other patient and surgical characteristics, would vary 
sufficiently across the country to account for the inter-hospital differences in surgical approach. There 
are also several important confounders, which could not be accounted for in the survival analysis. 
Reliable data regarding the utilisation and patient response to chemoradiotherapy for rectal cancer, 
and both neoadjuvant and adjuvant chemotherapy, were not available in NBOCA or HES data. In 
addition, post-operative complications, and functional return following the first operation for patients 
in the staged cohorts were not measured.  
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Patients were only included in this study if they underwent both CRC resection and liver resection. 
When comparing both operative mortality and long-term mortality in this cohort, it should be 
considered that to complete the treatment, patients in both the liver-first and bowel-first group must 
survive, and recover sufficiently from, the initial operation. There is inevitably patient ‘drop-out’ from 
such complex and prolonged treatment pathways, which may be significant. Several single centre 
cohort studies have reported that between 16 to 35% of liver-first and bowel-first patients fail to 
proceed to the second operation [27, 29, 32]. This may be secondary to either post-operative 
complications or disease progression. Proponents of a staged approach argue that the assessment of 
disease progression during the interval between first resection and second resection allows those with 
a poor prognosis to be excluded from surgery [6]. A potential disadvantage of the simultaneous 
approach is that it does not allow for such an assessment period. Studies comparing outcomes 
between staged and simultaneous cohorts will therefore over-sample patients with favourable tumour 
biology in the staged population, leading to selection bias in favour of the staged approaches.  
 
We found there to be wide variation in surgical approach according to hospital trust of diagnosis 
reflecting no clear consensus as to optimal management. The apparent variation in care seems to align 
with our previous work demonstrating patients with simultaneous liver metastases at diagnosis are 
more likely to receive a liver resection and have a survival advantage when compared to patients 
diagnosed at centres without on-site hepatobiliary services [14]. The presence of a hepatobiliary team 
on-site appeared to impact upon decision-making, as patients diagnosed at hospital trusts with such 
services on-site were more likely to undergo a simultaneous or liver first approach. Patients diagnosed 
at hospital trusts with no hepatobiliary MDT on-site may be undergoing CRC resection prior to 
referral to a hepatobiliary MDT for consideration of liver resection. 
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The clinico-pathological characteristics of patients undergoing a simultaneous and liver-first strategy 
were quite distinct, confirming that these are generally performed in highly selected patients. A liver-
first approach is commonly used in patients with more extensive hepatic disease [11]. This was 
suggested in the present cohort by the high rate of major liver resection in the liver-first group as well 
as increased used of techniques to maximise the future liver remnant. Liver-first patients will have 
been deemed by the colorectal and hepatobiliary MDTs fit enough to withstand systemic 
chemotherapy followed by two major operations. It therefore follows that liver-first patients in the 
present cohort were younger and had less co-morbidities than those in the bowel-first cohort. There 
also may be more treatment directed at attempting to cure a younger fitter patient. Synchronous 
resection increases the complexity of the surgical procedure and it is therefore notable that patients 
selected for a simultaneous approach tended to be older and have a higher ASA grade than patients 
undergoing alternative approaches. The safety of simultaneous resection when involving a minor 
resection in combination with high or low risk CRC resection has been demonstrated [33, 34] and it 
may be considered clinically appropriate to offer this strategy to higher risk patients with low volume 
liver disease to avoid the cumulative morbidly and mortality of separate interventions. Differences in 
the extent of liver metastases, age and comorbidities between patients undergoing each surgical 
strategy may act to cancel each other out, resulting in similar survival between the unmatched groups. 
For example, patients in the simultaneous group had less extensive liver metastases, yet they were 
more elderly with higher ASA than patients in the bowel-first cohort.  
 
The landmark survival analysis of the matched cohorts in the present study also showed no evidence 
of a difference in long-term survival between patients undergoing an alternative strategy to those 
undergoing a bowel-first approach. The limited studies comparing survival between the three 
strategies [27, 28] are hampered by direct comparison of strategies without accounting for selection 
bias in patients planned to have a staged approach. Our study demonstrates that the characteristics of 
the bowel-first patients matched to the simultaneous group were widely different to those of the 
bowel-first patients matched to the liver-first group. Furthermore, at which time point to begin the 
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comparison of the three groups varies throughout the literature. In the analysis of 1,004 patients who 
completed one of the three treatment strategies, Mayo and co-authors (2013) analysed long-term 
survival from 90-days after the date of the liver-directed operation [35]. This analysis therefore 
included the post-operative mortality associated with CRC resection for patients in the liver-first 
group, yet no post-operatively mortality for patients in the liver-first and simultaneous cohort. Broquet 
and co-authors (2010) analysed survival in 142 patients from the date of the last surgery, therefore 
comparing post-operative mortality of a combined liver and CRC resection in simultaneous patients to 
a single procedure in staged patients. In both of the aforementioned methods, the survival analysis 
start date for each patient varied from the date of diagnosis. In this study, survival in each cohort was 
estimated conditional on a patient’s survival to the landmark time to reduce such time bias.  
 
This study suggests that a liver-first or synchronous approach can achieve similar survival rates in 
selected cases to the conventional bowel-first approach for CRC patient with synchronous liver-
limited metastases. This study has also indicated that there is substantial variation in how patients 
with synchronous disease are managed. There may be scope for increased resection rates of liver 
metastases in either the liver-first or the simultaneous settings. Patients with synchronous disease 
should be discussed in a hepatobiliary MDT at the earliest point in their journey.  
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Table 1 Clinico-pathological characteristics and surgical details of patients diagnosed with 
synchronous liver metastases undergoing CRC resection and liver resection (n=1,830) 
    
Liver-first 
n=270 
Simultaneous 
n=259 
Bowel-first 
n=1,301 P-value 
Sex 
Male    173 (64.1) 141 (54.4)  814 (62.6)  
 0.033 
Female 97 (35.9)  118 (45.6)  487 (37.4)  
CRC site 
Right side      21 (7.8)  134 (51.7)  356 (27.4)  
 <0.001 
 
Left side 97 (35.9)  71 (27.4)  630 (48.4)  
Rectum   152 (56.3) 54 (20.9) 315 (24.2)  
IMD quintile 
1 (most deprived) 27 (10.1)  45 (17.5)  153 (11.8)  
 0.110 
2 53 (19.9)  51 (19.8)  233 (18.0)  
3 56 (21.0)  52 (20.2)  269 (20.8)  
4 71 (26.6)  54 (21.0) 293 (22.6)  
5 (least deprived) 60 (22.5)  55 (21.4)  346 (26.7)  
Missing  3 0 11  
Age (years) 
<60    122 (45.2)  73 (28.2)  397 (30.5)  
 <0.001 60-70 88 (32.6)  81 (31.3)  472 (36.3)  
>70 60 (22.2)     105 (40.5) 432 (33.2)  
Charlson co-morbidity 
score 
0    163 (61.1)     158 (61.7)  849 (66.6)  
0.097  
1 85 (31.8) 70 (27.3) 325 (25.5) 
2 19 (7.1)  28 (10.9)       100 (7.9)  
Missing  3 3 27  
Pathological T stage 
(primary tumour) 
T0-2 45 (17.3)  21 (8.2)  102 (8.0)  
 <0.001 
T3 173 (66.5)      146 (56.8)  790 (62.0) 
T4  42 (16.2)  90 (35.0)  382 (30.0) 
Missing  10 2 27  
Pathological N stage 
(primary tumour) 
N0 100 (38.5)     78 (30.5)   390 (30.6)  
0.042  
N1  94 (36.2)  110 (43.0) 484 (38.0) 
N2  66 (25.4)    68 (26.6)  401 (31.5) 
Missing  10 3  26  
ASA grade* 
1/2 187 (75.1) 169 (70.4)  995 (81.0)  
<0.001  3/4   62 (24.9)  71 (29.6)     234 (19.0) 
Missing 21 19   72 
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Major liver resection    127 (47.0)   40 (15 4)  535 (41.1) <0.001 
Combined ablation 41 (15.2)  20 (7.7)  148 (11.4) 0.026 
Two stage resection       10 (3.7)   2 (0.8)  21 (1.6) 0.026 
Portal vein embolisation       31 (11.5)  16 (6.2)  153 (11.8) 0.030 
Hepatobiliary surgery services at site of diagnosis  72 (26.7)  138 (53.3)    269 (20.7)  <0.001 
 
*assessed at time of CRC resection, ASA American Society of Anaesthesiologists, CRC colorectal cancer, IMD Index of Multiple 
Deprivation 
 
Table 2 Clinico-pathological characteristics and surgical details of propensity score-matched patients  
 
    
Liver-first 
N=207 
Bowel-first 
N=207   
Bowel-first 
N=198 
Simultaneous
N=198 
Sex 
Male 132 (63.8) 140 (67.6)   108 (54.6) 104 (52.5) 
Female 75 (36.2) 67 (32.4)   90 (45.5) 94 (47.5) 
CRC site 
Right side 12 (5.8) 8 (3.9)   94 (47.5) 84 (42.4) 
Left side 77 (37.2) 54 (26.1)   58 (29.3) 69 (34.9) 
Rectum 118 (57.0) 145 (70.1)   46 (23.2) 45 (22.7) 
IMD quintile 
1 (most deprived) 20 (9.7) 22 (10.6)   37 (18.7) 48 (24.2) 
2 40 (19.3) 41 (16.8)   35 (17.7) 34 (17.2) 
3 45 (21.7) 52 (25.1)   35 (17.7) 37 (18.7) 
4 54 (26.1) 52 (25.1)   45 (22.7) 42 (21.2) 
5 (least deprived) 48 (23.2) 40 (19.3)   46 (23.2) 37 (18.7) 
Age group 
0-64 95 (45.9) 98 (47.3)   55 (27.8) 63 (31.8) 
65-74 66 (31.9) 65 (31.4)   65 (32.8) 57 (28.8) 
75-84 46 (22.2) 44 (21.3)   78 (39.4) 78 (39.4) 
Charlson co-
morbidity score 
0 131 (63.3) 126 (60.9)   121 (61.1) 128 (64.7) 
1 61 (29.5) 65 (31.4)   56 (28.3) 52 (26.3) 
2 15 (7.3) 16 (7.7)   21 (10.6) 18 (9.1) 
Pathological T 
stage (primary 
tumour) 
T0-2 37 (17.9) 49 (23.7)   18 (9.1) 18 (9.1) 
T3 140 (67.6) 130 (62.8)   113 (57.1) 117 (59.1) 
T4 30 (14.5) 28 (13.5)   67 (33.8) 63 (31.8) 
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Pathological N 
stage (primary 
tumour) 
N0 79 (38.2) 85 (41.1) 64 (32.3) 72 (36.4)
N1 77 (37.2) 73 (35.3)   84 (42.4) 80 (40.4) 
N2 51 (24.6) 49 (23.7)   50 (25.3) 46 (23.2) 
ASA grade* 
1/2 160 (77.3) 153 (73.9)   145 (73.2) 148 (74.8) 
3/4 47 (22.7) 54 (26.1)   53 (26.8) 50 (25.3) 
Major liver resection 98 (47.3) 106 (51.2) 27 (13.6) 26 (13.1)
*assessed at time of CRC resection, ASA American Society of Anaesthesiologists, CRC colorectal cancer, IMD Index of Multiple 
Deprivation 
 
 
 
  
 
Figure 1 Trends in surgical strategy over study period according to year of diagnosis 
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Figure 2 Variation in surgical strategy according to English National Health Service hospital trust of 
diagnosis 
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Figure 3 Landmark analysis of survival in patients surviving a minimum of 1 year after diagnosis or, 
if the second procedure had not been undertaken in the year following diagnosis, more than 90-days 
from their second procedure, according to surgical strategy: a & b in all patients, c & d in propensity 
score-matched patients. a P=0.638, b P=0.788 (log rank test)  
 
